Case Studies

Occupational Therapy, Valuation of New Assessment Codes

Remote Therapeutic Monitoring

Cardiovascular Technologies

Lumbar Spine Stenosis Device

Non-Opioid Device Pain Relief Product

AI Device for Osteoporosis Assessment

Osseochondral Knee Implant

Wound Product

Diabetic Devices and Supplies

Commercial Strategy for Orphan Disease Commercial Strategy

Part A and Part B Drug Codes

Alzheimer’s Diagnostic and Drug

Pharmacogenomic Panel

Osteoarthritis Pain Drug

Colorectal Cancer Screening Test

Minimal Residual Disease Test

Payer Reimbursement Landscape

CPT Coding

HCPCS Coding

Payer Workshops on Clinical Endpoints and P&R for Novel Biologic

Commercial Contracting Process, Evaluations, and Metrics

Payer/KOL P&R Input to New Oncology Biologic Development Plan

Launch Planning and Implementation Support for Novel Biologic

Evaluation of Biosimilar Utilization by Hospital Types

Advocacy Coalition for Uptake of Comprehensive Genomic Profiling

Physician State Society Federal and State Policy Counsel

Community Oncology Practice Federal and State Policy Counsel

Biopharmaceutical Policy Analysis and Advocacy Strategy

Medicaid Reimbursement Landscape Analysis

Self-Administered Drug Exclusion List

Most Favored Nation (MFN) Model

Insulin Coverage and Affordability

Mental Health Drug

Novel Treatment for Rare Pediatric Genetic Disorder

Medicare Home Infusion Therapy Benefit

Medicare Part D Benefit Redesign

“Government Negotiation” of Drug Prices

White Paper Development on Policy Landscape for Bio/Pharma Industry

Secure Channel Relationships

Medicare Coverage

AMCP Advisory Board

Retrospective Study: SGLT-2 Inhibitors Rx Disparities and Affordability Among Medicare Patients with Diabetes

Assessing the Hypertension Market in Medicare and Medicaid Populations

Go-to-Market Strategy Development and Execution for Progyny

Strategic Planning for Part B Launch

Strategic Partnerships for Digital Health Clients

Device Concept, Creation, and Commercialization

Type 2 Diabetes Digital Therapeutics Reimbursement Strategy

Product Positioning for a Novel Cancer Therapy

Launch Roadmap for a Novel Vaccine

Value Based Payment for Gene Therapy

Metastatic Melanoma Cell Therapy Launch

U.S. Respiratory Syncytial Virus (RSV) Vaccine

Gene Therapy Pricing

Cell Therapy Pricing

Pharma ELTs

Rare and Ultra Rare Therapeutics

U.S. Launch of a Ex-U.S. Oncology Agent

Physician-Administered Drug Commercialization

Next-Generation Sequencing-Based Multi-Cancer Panel

Liquid Biopsy Assay

Novel International Molecular Diagnostic System

Prostate Cancer Prognostic Assay

Evaluation and Strategic Planning for Combination Pricing

Value/Price Message Development for Executive Team

Evaluation of Indication-Based Pricing for Oncology Biologic

Demonstrate Value to Payers

Segmentation and Understanding Payers